Abivax's oral miRNA-124 enhancer, obefazimod, demonstrated significant efficacy in two phase 3 trials for moderately to severely active ulcerative colitis, achieving a 16.4% placebo-adjusted clinical remission at eight weeks. The 50 mg dose met all primary and secondary endpoints, while the 25 mg dose showed positive response rates in pooled analyses. Safety profiles were consistent with earlier studies. Ongoing maintenance trials will further evaluate long-term effects. These results position Abivax's candidate as a leading oral treatment in inflammatory bowel disease, sparking a stock price surge exceeding 500%. Regulatory filings are anticipated in late 2026.